Arcellx, CAR T Therapy, CART DDBCMA, chimeric antigen receptor, Kite Pharma, multiple myeloma
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic..
Abecma, B-cell maturation antigen, chimeric antigen receptor, idecabtagene vicleucel, proteasome inhibitor, refractory multiple myeloma
The FDA has approved idecabtagene vicleucel for the treatment of multiple myeloma
August 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therap..